Europe Heparin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Europe Heparin Market Analysis

The Europe Heparin Market size is estimated at USD 2.40 billion in 2024, and is expected to reach USD 3.30 billion by 2029, growing at a CAGR of 6.60% during the forecast period (2024-2029).

Factors such as the rising prevalence of chronic diseases and the increasing geriatric population in Europe are expected to boost market growth. The rising prevalence of chronic disorders around European countries, such as coronary artery disease, heart attacks, and cancer, is a major factor driving the market growth as it is expected to boost the usage of heparin for the management of the disease. For instance, according to the data updated by the European Union in September 2022, cardiovascular diseases are one of the leading causes of morbidity in the European Union. Cardiovascular diseases cover a broad group of medical problems that affect the circulatory system (the heart and blood vessels), often resulting from atherosclerosis, the abnormal build-up of plaque that is made of, among constituents, cholesterol or fatty substances that are deposited on the inside walls of a person’s arteries.

Some of the most common diseases that affect the circulatory system include ischaemic heart disease (heart attacks) and cerebrovascular diseases (strokes). Hence, the high prevalence of such heart disorders in European countries is expected to drive the adoption of heparin, which would drive the growth of the market.

According to the data updated by the Santé Publique France in July 2023, over 433,000 new cancer diagnoses were recorded in 2023 in France, nearly doubling the 216,000 cases found in 1990. The source also stated that new cancer cases in women were increasing faster, with the median age of diagnosis being 68 years old (compared to 70 years old for men). Thus, the increasing prevalence of cancer in France is also expected to boost the demand for heparin, which is often used for the treatment of symptoms such as venous thromboembolism in cancer patients.

In addition, the increasing geriatric population in the region is also expected to enhance market growth as heparin is often used for the management of chronic diseases in older patients. For instance, according to the data updated by the UN World Population Fund Dashboard in 2023, around 23% of the total population in Germany was 65 years or older in 2023. Thus, the high geriatric population in these countries is also expected to increase the usage of heparin.

Therefore, owing to the aforementioned factors, such as the rising prevalence of chronic disorders and the growing geriatric population, the market is anticipated to grow over the forecast period. However, the side effects of heparin and the emergence of oral coagulants are likely to impede market growth.

Europe Heparin Market Trends

The Low Molecular Weight Heparin (LMWH) Segment is Expected to Witness Significant Growth Over the Forecast Period

Europe Heparin Industry Segmentation

Heparin is an anticoagulant that is used to decrease the clotting ability of blood and help prevent harmful clots from forming in blood vessels.

The European heparin market is segmented by product, source, application, and geography. By product, the market is segmented into unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). By source, the market is segmented into bovine and porcine. By application, the market is segmented into deep vein thrombosis (DVT), atrial fibrillation and heart attack, coronary artery disease, and other applications. By geography, the market is segmented into Germany, the United Kingdom, France, Italy, Spain, and Rest of Europe. The report offers the value (USD) for all the above segments.